Federal Register / Vol. 69, No. 193 / Wednesday, October 6, 2004 / Notices 59933

biological and life sciences, food 

science, risk assessment, and other 

relevant scientific and technical 

disciplines. The agency is particularly 

interested in considering candidates 

with a comprehensive background in 

food technology, molecular biology, 

genetics, biotechnology, and a variety of 

medical specialties, as many issues 

brought before the Committee involve 

medical or epidemiological impact on 

nutrients, additives, contaminants, or 

other constituents of the diet, such as 

dietary supplements. The term of office 

is for up to 4 years, depending on the 

appointment date.

IV. Nomination Procedures

Any interested person may nominate 

one or more qualified persons for 

membership on the Parent Committee or 

one or more of the subcommittees. Selfnominations are also accepted. 

Nominations shall include the name of 

the committee or subcommittee, a 

complete curriculum vitae of each 

nominee, current business address and 

telephone number, and shall state that 

the nominee is aware of the nomination, 

is willing to serve as a member of the 

Parent Committee or subcommittee 

(name of committee/subcommittee(s) 

must be specified), and appears to have 

no conflict of interest that would 

preclude membership. FDA will ask the 

potential candidates to provide detailed 

information concerning such matters as 

financial holdings, employment, and 

research grants and/or contracts to 

permit evaluation of possible sources of 

conflicts of interest.

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2) and 21 CFR part 14, 

relating to advisory committees.

Dated: October 1, 2004.

Sheila Dearybury Walcoff,

Associate Commissioner for External 

Relations.

[FR Doc. 04–22498 Filed 10–5–04; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES

Food and Drug Administration

Memorandum of Understanding 

Between the State of Iowa, Department 

of Public Health, Bureau of 

Radiological Health and the Food and 

Drug Administration, Center for 

Devices and Radiological Health

AGENCY: Food and Drug Administration, 

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug 

Administration (FDA) is providing 

notice of a memorandum of 

understanding (MOU) between the State 

of Iowa, through the Iowa Department of 

Public Health, Bureau of Radiological 

Health and the Food and Drug 

Administration, Center for Devices and 

Radiological Health, to continue to 

conduct a State as certifiers program in 

Iowa under the Mammography Quality 

Standards Act.

DATES: The agreement became effective 

August 18, 2004.

FOR FURTHER INFORMATION CONTACT:

Joanne Choy, Division of Mammography 

Quality and Radiation Programs (HFZ–

240), Food and Drug Administration, 

1350 Piccard Dr., Rockville, MD 20850, 

301–827–2903, or e-mail: 

jkc@cdrh.fda.gov.

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 20.108(c), 

which states that all written agreements 

and MOUs between FDA and others 

shall be published in the Federal 

Register, the agency is publishing notice 

of this MOU.

Dated: September 30, 2004.

Jeffrey Shuren,

Assistant Commissioner for Policy.

BILLING CODE 4160–01–S

59934 Federal Register / Vol. 69, No. 193 / Wednesday, October 6, 2004 / Notices 


EN06OC04.028</GPH>
Federal Register / Vol. 69, No. 193 / Wednesday, October 6, 2004 / Notices 59935


EN06OC04.029</GPH>
59936 Federal Register / Vol. 69, No. 193 / Wednesday, October 6, 2004 / Notices 


EN06OC04.030</GPH>
Federal Register / Vol. 69, No. 193 / Wednesday, October 6, 2004 / Notices 59937


EN06OC04.031</GPH>
59938 Federal Register / Vol. 69, No. 193 / Wednesday, October 6, 2004 / Notices 

[FR Doc. 04–22497 Filed 10–5–04; 8:45 am]

BILLING CODE 4160–01–C

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Institute Initial Review Group, Subcommittee 

I—Career Development NCI–I Initial Review 

of Training Grants. 

Date: November 3–4, 2004. 

Time: 7:30 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Wyndham City Center Hotel, 1143 

New Hampshire Ave., NW., Washington, DC 

20037. 

Contact Person: Robert Bird, PhD, 

Scientific Review Administrator, Resources 

and Training Review Branch, National 

Cancer Institute, National Institutes of 

Health, 6116 Executive Blvd., MSC 8328, 

Room 8113, Bethesda, MD 20892–8328, 301–

496–7978, birdr@mail.nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93,393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 29, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–22404 Filed 10–5–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Spore In 

Myeloma And Genitourinary Cancer. 

Date: December 1–2, 2004. 

Time: 6 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Wyndham Washington, DC, 1400 M 

Street, NW., Washington, DC 20005. 

Contact Person: Brian E. Wojcik, PhD, 

Scientific Review Administrator, Grants


EN06OC04.032</GPH>